SeaCrest Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

SeaCrest Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-107	Closed	-$10K	–	680
2019 Q1	$10K	Buy	107 +41	+62%	+$3.8K	﹤0.01%	1517
2018 Q4	$6K	Sell	66 -34	-34%	-$3.23K	﹤0.01%	1638
2018 Q3	$10K	Hold	100	–	–	﹤0.01%	1641
2018 Q2	$9K	Buy	100 +91	+1,011%	+$7.97K	﹤0.01%	1645
2018 Q1	$1K	Hold	9	–	–	﹤0.01%	2065
2017 Q4	$1K	Buy	+9	New	+$783	﹤0.01%	2076

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

SeaCrest Wealth Management's BMRN Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 107 shares — an estimated $10K sold.

SeaCrest Wealth Management first reported a position in BMRN in Q4 2017 and held it in 6 quarters. The position peaked at $10K in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

SeaCrest Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 107 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $10K.
SeaCrest Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's BioMarin Pharmaceuticals position peaked at $10K in Q1 2019.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.